Possible relation of p53 and mdm-2 oncoprotein expression in thyroid carcinoma: A molecular-pathological and immunohistochemical study on paraffin-embedded tissue

Endocrine Pathology

Volumn 7, Issue 2, 1996, Pages 121-130

  Schmid, Kurt W ^a   Bankfalvi, Agnes ^a   Mücke, Swantja ^a   Öfner, Dietmar ^a   Riehemann, Kristina ^a   Schröder, Sören ^b   Stücker, Andrea ^a   Tötsch, Martin ^c   Dockhorn Dworniczak, Barbara ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Immunohistochemistry; mdm 2; p53; Polymerase chain reaction single strand conformation polymorphism (PCR SSCP) analysis; Thyroid carcinoma

Indexed keywords

EID: 0142072360     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02739971     Document Type: Article

References (35)

1. Lane DP, Benchimol S. p53: oncogene or antioncogene. Gene Dev 4:1-8, 1990.
2. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D. The 1993 Walter Hubert lecture: the role of the p53 tumour suppressor gene in tumorigenesis. Br J Cancer 69:409-416, 1993.
3. Soares P, Sobrinho-Simões M. Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Pathol Res Pract 191:304-317, 1995.
4. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B. p53 gene mutations occur in combinations with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990.
5. Silvestrini F, Benini E, Daidone MG. p53 as an independent prognostic marker in lymphnode negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993.
6. Reznikoff CA, Kao C, Messing EM, Newton M, Swaminathan S. A molecular genetic model of human bladder carcinogenesis. Sem Cancer Biol 4:143-152, 1993.
7. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166:329,330, 1992.
8. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263, 1979.
9. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus ElB-58kD tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kD cellular protein in transformed cells. Cell 28:387-394, 1982.
10. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins. Science 248:76-79, 1990.
11. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, et al. p53 mutations, ras mutations and p53 heat shock protein complexes. Cancer Res 51:4090-4096, 1991.
12. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237-1245, 1992.
13. Öfner D, Maier H, Riedmann B, Holzberger P, Nogler M, Tötsch M, Bankfalvi A, Winde G, Böcker W, Schmid KW. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal adenocarcinoma - clinicopathologic study of 109 consecutive cases demonstrating lack of long-term prognostic significance. J Clin Pathol Mol Pathol 48:M12-M16, 1995.
14. Wright PA, Lemoine NR, Goretzki P, Wyllie FS, Bond J, Röher H-D, Williams ED, Wynford-Thomas D. Mutations of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6:1693-1697, 1991.
15. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M. Unique association of p53 mutation with undifferentiated but not differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371, 1992.
16. Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujito S, Miya A, Mori T, Nishisho I, Takai S. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83:1293-1298, 1992.
17. Yana I, Nakamura T, Shin E, Karakawa E, Kurahashi H, Kurita Y, Kabayashi T, Mori T, Nishisho I, Takai S. Inactivation of the p53 gene is not required or tumorigenesis of medullary thyroid carcinoma or pheochromocytoma. Jpn J Cancer Res 83:1113-1116, 1992.
18. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 52:5061-5064, 1992.
19. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760, 1993.
20. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184, 1993.
21. Dockhorn-Dworniczak B, Schröder S, Dantcheva R, Tötsch M, Stücker A, Brömmelkamp E, Bankfalvi A, Böcker W, Schmid KW. The role of p53 tumor suppressor gene in human thyroid cancer. Exp Clin Endocrinol 101:39-46, 1993.
22. Schmid KW, Stücker A, Caspari S, Tötsch M, Schröder S, Böcker W, Dockhorn-Dworniczak B. Molecular-pathological and immunohistochemical investigations of p53 in human thyroid carcinomas. Pathol Res Pract 189:805A, 1993.
23. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machiami R. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381, 1993.
24. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T, Machiami R. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 3:9-14, 1994.
25. Soares P, Cameselle-Teijeiro J, Sobrinho-Simões M. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 24:205-210, 1994.
26. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 47:337-339, 1994.
27. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. WHO international histological classification of tumours. 2nd ed. Berlin: Spinger-Verlag, 1988.
28. Bankfalvi A, Navabi H, Bier B, Böcker W, Jasani B, Schmid KW. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemisrry. J Pathol 174:223-228, 1994.
29. Morgan JM, Navabi H, Schmid KW, Jasani B. Possible role of tissue bound calcium ions in citrate mediated high temperature antigen retrieval. J Pathol 174:301-307, 1994.
30. Maniatis D, Fritsch J, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1992.
31. Allen RC, Graves G, Budowle B. Polymerase chain reaction amplification products separated on rehydratable polyacrylamine gels and stained with silver. Biotechniques 7:736-744, 1989.
32. Goldman D, Merril CR. Silver staining of DNA in polyacryamide gels: linearity and effect of fragment size. Electrophoresis 3: 24-26, 1982.
33. Esrig D, Spruck CH III, Nichols PW, Chaiwun PW, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397, 1993.
34. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenothypic patterns. Int J Cancer 56:347-353, 1994.
35. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Gene Dev 7:1126-1132, 1993.